Ravulizumab (Ultomiris)

Decision Date:
May 2021


RED8: NICE TA698:  Treatment of adults with paroxysmal nocturnal haemoglobinuria with haemolysis with clinical symptoms indicative of high disease activity and those treated with eculizumab for 6 months who are clinically stable. (Decision date - June 2021) 

RED: Treatment of adults and children with a body weight ≥10kg with atypical haemolytic uraemic syndrome who are complement inhibitor treatment-naïve or have received eculizumab for ≥3 months and have evidence of response to eculizumab

Red Drug Classifications

  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire CCG

Derby and Derbyshire CCG

Please click the button to navigate to our app

Redirect to app